| scholarly article | Q13442814 |
| P50 | author | Tanuja Chitnis | Q30353265 |
| P2093 | author name string | Angelo Ghezzi | |
| Dieter A Häring | |||
| Daniela Pohl | |||
| Rolf Meinert | |||
| Annik K-Laflamme | |||
| P2860 | cites work | Impact of diagnosis and early treatment on the course of multiple sclerosis | Q27023867 |
| Brain health: time matters in multiple sclerosis | Q28076642 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Clinical relevance of brain volume measures in multiple sclerosis | Q30738659 | ||
| Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial | Q30789784 | ||
| Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial | Q34611762 | ||
| Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis | Q35116652 | ||
| Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial | Q35533579 | ||
| The transition from relapsing-remitting MS to irreversible disability: clinical evaluation | Q35599133 | ||
| Extensive acute axonal damage in pediatric multiple sclerosis lesions | Q35913394 | ||
| Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study | Q36859528 | ||
| Natural history of multiple sclerosis: long-term prognostic factors | Q37857985 | ||
| Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review | Q39253386 | ||
| Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40192733 | ||
| Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years | Q41067358 | ||
| Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. | Q41644136 | ||
| Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis | Q43595394 | ||
| Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom | Q46406749 | ||
| Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability | Q47163542 | ||
| Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments | Q47200732 | ||
| Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? | Q47749682 | ||
| Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome | Q48256119 | ||
| Age at disability milestones in multiple sclerosis | Q48686550 | ||
| Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis | Q49072224 | ||
| Importance of early treatment initiation in the clinical course of multiple sclerosis. | Q50568937 | ||
| Early onset multiple sclerosis: a longitudinal study. | Q50708682 | ||
| Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. | Q51422478 | ||
| Natural history of multiple sclerosis with childhood onset. | Q51749568 | ||
| Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. | Q53425063 | ||
| Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials. | Q55108719 | ||
| Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis | Q57039722 | ||
| Long-term outcome of paediatric-onset multiple sclerosis: a population-based study | Q63352438 | ||
| Pediatric multiple sclerosis | Q84852114 | ||
| P433 | issue | 2 | |
| P921 | main subject | relapsing-remitting multiple sclerosis | Q18555066 |
| P304 | page(s) | 461-475 | |
| P577 | publication date | 2019-07-19 | |
| P1433 | published in | Neurology and therapy | Q26842826 |
| P1476 | title | Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials | |
| P478 | volume | 8 |
Search more.